Comparison of time to therapy initiation, therapeutic strategies and survival in patients with MDS IB1, IB2 and AML-MR using data of the duesseldorf registries

Felicitas Schulz, Catharina Mundt, Annika Kasprzak, Paul Jaeger, Andrea Kuendgen, Corinna Strupp, Norbert Gattermann, Kathrin Nachtkamp, Sascha Dietrich, Guido Kobbe, Ulrich Germing

Open source

DOI
10.1007/s00277-026-07250-3
Published
2026-08-26
Container
Annals of Hematology
Publisher
Springer Science and Business Media LLC
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1007/s00277-026-07250-3,
  title = {Comparison of time to therapy initiation, therapeutic strategies and survival in patients with MDS IB1, IB2 and AML-MR using data of the duesseldorf registries},
  author = {Felicitas Schulz and Catharina Mundt and Annika Kasprzak and Paul Jaeger and Andrea Kuendgen and Corinna Strupp and Norbert Gattermann and Kathrin Nachtkamp and Sascha Dietrich and Guido Kobbe and Ulrich Germing},
  year = {2026},
  journal = {Annals of Hematology},
  doi = {10.1007/s00277-026-07250-3},
  url = {https://doi.org/10.1007/s00277-026-07250-3}
}

RIS

TY  - JOUR
TI  - Comparison of time to therapy initiation, therapeutic strategies and survival in patients with MDS IB1, IB2 and AML-MR using data of the duesseldorf registries
AU  - Felicitas Schulz
AU  - Catharina Mundt
AU  - Annika Kasprzak
AU  - Paul Jaeger
AU  - Andrea Kuendgen
AU  - Corinna Strupp
AU  - Norbert Gattermann
AU  - Kathrin Nachtkamp
AU  - Sascha Dietrich
AU  - Guido Kobbe
AU  - Ulrich Germing
PY  - 2026
JO  - Annals of Hematology
DO  - 10.1007/s00277-026-07250-3
UR  - https://doi.org/10.1007/s00277-026-07250-3
ER  - 

APA

Schulz, F., Mundt, C., Kasprzak, A., Jaeger, P., Kuendgen, A., Strupp, C., Gattermann, N., Nachtkamp, K., Dietrich, S., Kobbe, G., & Germing, U. (2026). Comparison of time to therapy initiation, therapeutic strategies and survival in patients with MDS IB1, IB2 and AML-MR using data of the duesseldorf registries. Annals of Hematology. https://doi.org/10.1007/s00277-026-07250-3

Source records